Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02144103
Recruitment Status : Unknown
Verified July 2017 by Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation.
Recruitment status was:  Enrolling by invitation
First Posted : May 21, 2014
Last Update Posted : July 21, 2017
Sponsor:
Information provided by (Responsible Party):
Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation

Brief Summary:
Autologous adipose-derived regenerative cells (ADRC) extracted using Celution 800/CRS System (Cytori Therapeutics Inc) from a portion of the fat harvested from the patient's front abdominal wall. ADRC will be administered one-time into subtenon space of patient's eyeball. This is a single arm study with no control. All patients receive cell therapy.

Condition or disease Intervention/treatment Phase
Retinal Degeneration Primary Open-Angle Glaucoma Other: Subtenon administration of autologous ADRC Procedure: Liposuction Device: ADRC isolation Phase 1 Phase 2

Detailed Description:

Fat tissue obtainment:

Subjects will undergo liposuction under local anesthesia. In this procedure, Ringer's solution with the anesthetic lidocaine and vasoconstrictor adrenaline infused into the adipose compartment to minimize blood loss and contamination of the tissue by peripheral blood cells. 15 minutes later a hollow blunt-tipped 3 mm cannula introduced into the subcutaneous space through small (0.5 cm) incision. The cannula attached to syringe and under gentle suction moved through the adipose compartment, mechanically disrupting the fat tissue. Aspirate volume - approximately 150-200 cc. Procedure time - 30 minutes.

ADRC isolation:

Aspirated fat tissue placed into sterile vessel which inserted into Celution 800/CRS System (Cytori Therapeutics Inc) - closed system for automated and standardized extraction and concentration of ADRC. Celution 800/CRS System drains excess of fluid from fat tissue and estimate it's volume After that lipoaspirate washed extensively with equal volumes of Ringer's solution to remove blood. At the end of this process System indicates required volume of enzyme reagent (Celase®) which should be added immediately by operator. After enzyme treatment Celution 800/CRS System automatically transfers isolated ADRC into washing compartment where ADRC washed and concentrated in 5 mL suspension. Tissue processing time - approximately 60 minutes. ADRC suspension match all requirements listed in technical documentation for Celution 800/CRS System. Obtained ADRC divided into 2 portions. First portion (0.2-0.5 mL) used for counting, viability and sterility assessment. Second portion placed into sterile syringe for injection.

Subtenon injection of ADRC:

Antiseptic and anesthetic solutions instilled into conjunctival sac. After that blepharostat installed. The patient is asked to look in opposite to the injection side direction. Doctor inserts a needle into inferior temporal quadrant between rectus muscles,10-12 mm from the limbus. Needle should be moved slowly, as close as possible to the eyeball. After needle placement at the depth of 5-7 mm doctor injects concentrated solution of ADRC (up to 0,5 ml per single injection). Injection is made by insulin syringe with a needle size 0.45 mm * 12mm (26 G).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effectiveness and Safety of Subtenon Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration
Actual Study Start Date : May 2014
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : January 2019


Arm Intervention/treatment
Experimental: ADRC injection
Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected into subtenon space of patient's eye.
Other: Subtenon administration of autologous ADRC
Procedure: Liposuction
Device: ADRC isolation
ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol




Primary Outcome Measures :
  1. SAEs and SARs monitoring [ Time Frame: 4 weeks after treatment ]
    Types, probability and severity of treatment emergent serious adverse events (SAEs) and serious adverse reactions (SARs)


Secondary Outcome Measures :
  1. Change in visual acuty [ Time Frame: Follow up to completion (up to 48 weeks after treatment) ]
    Change from baseline in visual acuity assessed by visual acuty test

  2. Changes in structures of fundus of the eye-1 [ Time Frame: Follow up to completion (up to 48 weeks after treatment) ]
    Changes in structures of fundus of the eye assessed by funduscopy: changes of configuration and size of optic disc, neuroretinal rim thinning, degree of optic disc pallor, hemorrhages on the optic nerve and retina, vascular changes, presence of degenerative changes of retina, optic disc drusen, edema and retinal detachment.

  3. Changes in structures of fundus of the eye-2 [ Time Frame: Follow up to completion (up to 48 weeks after treatment) ]
    Changes in structures of fundus of the eye assessed by optical coherence tomography: changes of optic disc, neuroretinal rim and macula, retinal nerve fiber layer thickness.

  4. Change in visual field [ Time Frame: Follow up to completion (up to 48 weeks after treatment) ]
    Change from baseline in visual field assessed by computer perimetry

  5. Change in retinal flicker responce [ Time Frame: Follow up to completion (up to 48 weeks after treatment) ]
    Change from baseline in critical flicker fusion threshold

  6. Change in intraocular pressure [ Time Frame: Follow up to completion (up to 48 weeks after treatment) ]
    Change from baseline in intraocular pressure assessed by pneumotonometry and tonography

  7. Quality of life monitoring [ Time Frame: Follow up to completion (up to 48 weeks after treatment) ]
    Quality of life estimated by validated questionnaires: the Short Form (36) Health Survey (SF-36)., Visual Functioning-14 Quality of Life (VF-14 QOL) and Glaucoma Quality of Life-15 (GQL-15)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient suffers from primary open-angle glaucoma (II and III stages; singe eye or both eyes) at least for 6 months
  • Intraocular pressure is stable for at least for 3 months
  • Visual acuity of each eye (measured by using visual acuity charts projector) not less than 0,1
  • Patient is familiar with Participant information sheet
  • Patient signed informed consent form

Non-inclusion Criteria:

  • Contraindications to the local anesthesia or medical history of allergic reactions to local anesthetics
  • Any anomalies or conditions of at least one eye which can limit tonometry implementation
  • Inflammatory disease of at least one eye or auxiliary apparatus (both infectious and non-infectious etiology: conjunctivitis, keratitis, uveitis, dacryocystitis etc.)
  • Medical history of surgery on at least one eye during preceding 6 months.
  • Medical history of heavy traumatic injury of eyes
  • Patient has a cataract with high degree of lens opacification which can limit planned eye examination
  • Patient prescribed for systemic corticosteroids or other medications treatment with proven effect leading on intraocular pressure increase
  • Medical history or present dry eye syndrome accompanied by corneal and conjunctival xerosis
  • Subcompensated or decompensated forms of chronic diseases of internal organs
  • Clinically significant abnormalities in results of laboratory tests
  • Any conditions limiting compliance (dementia, neuropsychiatric disease, drug and alcohol abuse etc.)
  • Participation in other clinical trials (or administration of investigational drugs) during 3 months prior inclusion
  • Patients with malignant tumors including postoperative period, patients receiving chemotherapy and/or radiotherapy.
  • Patient's activated partial thromboplastin time exceeds normal levels more than 1,8 times
  • Patients prescribed for anticoagulants treatment or patient received anticoagulants at least one hour prior lipoaspiration
  • Medical history of heterotopic ossifications
  • Patients prescribed for glycoprotein inhibitors treatment
  • Acute vascular pathology
  • Age-related macular degeneration

Exclusion Criteria:

  • Patient's refusal from the further participation in trial
  • Patient's refusal from compliance with the requirements of contraception during the participation in research
  • Chronic kidney disease IV- V stages (creatinine clearance < 30 mL/min estimated by Cockroft-Gault formula)
  • Confirmed syphilis, HIV, hepatitis B or C infections

Dropout Criteria:

  • Direct indications on immediate initiation of treatment with medications with proven effect leading to intraocular pressure increase
  • Pregnancy
  • Development of cataract with high degree of lens opacification which can limit planned eye examination

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02144103


Locations
Layout table for location information
Russian Federation
Federal State Budgetary Institution "Outpatient Health Center №1" of the Business Administration for the President of the Russian Federation
Moscow, Russian Federation, 119002
Federal State Budgetary Institution "Central Clinical Hospital with Outpatient Health Center" of the Business Administration for the President of the Russian Federation; Center for Biomedical Technologies
Moscow, Russian Federation, 121359
Sponsors and Collaborators
Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
Investigators
Layout table for investigator information
Study Director: Alina K Drakon, MD Federal State Budgetary Institution "Central Clinical Hospital with Outpatient Health Center" of the Business Administration for the President of the Russian Federation
Principal Investigator: Ilya I Eremin, MD, PhD Federal State Budgetary Institution "Central Clinical Hospital with Outpatient Health Center" of the Business Administration for the President of the Russian Federation; Center for Biomedical Technologies
Principal Investigator: Julia P Sotnikova, MD Federal State Budgetary Institution "Outpatient Health Center №1" of the Business Administration for the President of the Russian Federation

Layout table for additonal information
Responsible Party: Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
ClinicalTrials.gov Identifier: NCT02144103     History of Changes
Other Study ID Numbers: RU-CCH-02-01-14
First Posted: May 21, 2014    Key Record Dates
Last Update Posted: July 21, 2017
Last Verified: July 2017

Keywords provided by Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation:
Retinal ganglion cell degeneration
Adipose-derived regenerative cells
Stem cells
Glaucomatous Neurodegeneration
Retinal Degeneration
Primary Open-Angle Glaucoma
Optic Neuropathy
Intraocular pressure
Optic nerve atrophy
Subtenon injection
Glaucomatous damage
ADRC
Fat tissue

Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma
Glaucoma, Open-Angle
Retinal Degeneration
Nerve Degeneration
Ocular Hypertension
Eye Diseases
Pathologic Processes
Eye Diseases, Hereditary
Retinal Diseases